A dual inhibitor of PTP-1B and TC-PTP has shown to induce anti-tumor immunity in animal models of cancer resistant to PD-1 blockade (34) and is currently being investigated in a phase 1 study of advanced solid tumors (ClinicalTrials.gov identifier NCT04777994). Here, PTPN1 is linked to cancer.